Thomas G. Gleason, MD, has been awarded a National Institutes of Health (NIH) RO1 grant for the study “ROS mechanisms in BAV aortopathy.”
Ascending thoracic aortic aneurysm (ATAA) predisposes to aortic dissection and/or rupture, a major cause of death worldwide. Patients with congenital bicuspid aortic valve (BAV) represent the largest cohort of patients with ATAA and have been presumptively assumed to have a greater risk of aortic catastrophe than patients with ATAA and a tricuspid aortic valve (TAV). An incomplete understanding of the complex interplay of cellular, molecular and biomechanical alterations underlying ATAAs in both BAV and TAV patient populations continues to impede progress in aortic catastrophe-risk adjudication and patient-specific care of ATAAs. Consequently, there is a critically unmet need for better diagnostic tools that comprehensively evaluate the pathobiological state of an ATAA in order to more accurately predict and thus mitigate dissection risk in a patient-specific manner.
The two primary objectives of this awarded project are 1) to identify the inciting factors of oxidative stress-induced aortic extracellular matrix remodeling (i.e. aneurysm formation) and 2) develop a multi-parameter, patient-specific (bio)imaging-based interrogation strategy, designed from newly established correlations of biological, biomechanical and imaging indices, to predict aneurysm progression and/or dissection potential.
Thomas G. Gleason, MD
Chief, Division of Cardiac Surgery, Brigham and Women’s Hospital
Co-Executive Director, Heart and Vascular Center
Member of the Faculty of Surgery, Harvard Medical School
A graduate of Middlebury College (BS) and Rush Medical College (MD), Dr. Gleason completed his general surgical internship and residency at the University of Virginia, where he also obtained a Master of Science in immunology. He completed a cardiothoracic surgery residency and an advanced cardiac and thoracic aortic fellowship at the University of Pennsylvania. He then held faculty positions at the University of Pennsylvania, Northwestern University and the University of Pittsburgh before joining the faculty of the Department of Surgery at Brigham and Women’s Hospital and Harvard Medical School.
Dr. Gleason has extensive clinical experience managing patients with valvular heart disease, thoracic aortic disease, hypertrophic obstructive cardiomyopathy, coronary artery disease and atrial fibrillation. His clinical research interests are focused on the development and refinement of novel valve therapies, particularly aortic valve repair strategies, and in developing a systematic approach toward the management of aortic dissections, while his longstanding basic science research interest has been devoted to the study of the aortopathy associated with congenital bicuspid aortic valves (BAV)—the subject of his latest RO1 grant.
Dr. Gleason is a member of the American Society for Clinical Investigation (ASCI), the American Surgical Association (ASA) and the American Association for Thoracic Surgery (AATS). He was a permanent member (2014-2019) of the Bioengineering, Technology, and Surgical Sciences (BTSS) Study Section for the Center for Scientific Review at the National Institutes of Health (NIH). He serves on the National Steering Committee for the STS/ACC TVT Registry and is co-chair of the Research and Publications Committee for the TVT Registry. He is a fellow of the American Heart Association (AHA), the American College of Surgeons (ACS), the American College of Cardiology (ACC) and the American College of Chest Physicians (CHEST).